J&J, Novartis second quarter sales rise

Share this article:
Johnson & Johnson reported a 13% rise in sales overall to $15.1 billion from $13.4 billion.
Major growth came from J&J's consumer business, where sales rose 49% to $3.6 billion due to the acquisition of Pfizer's consumer products business late last year.
J&J's pharmaceuticals unit posted a sales increase of 5.8% to $6.1 billion for the second quarter. Sales of J&J's antipsychotic medicines, including its top medicine Risperdal, rose 10% to $1.14 billion. Blockbuster migraine drug Topamax sold $578 million in the second quarter, up 17% from a year ago.
Novartis' sales, excluding the company's baby-food business, rose 10% to $9.4 billion from $8.5.
Novartis said it plans to use proceeds from the sale to fund targeted acquisitions and repurchase up to around $4 billion of Novartis shares by February 2008, as part of an ongoing buyback program. 
Despite second quarter sales growth, Novartis has lowered its sales outlook for the second half due to earlier than expected generic competition for hypertension drug Lotrel, the suspension of bowel drug Zelnorm in the US, and generic competition for antifungal Lamisil. 
Meanwhile, Pfizer is scheduled to release its second quarter results during a call with analysts on Wednesday.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.